Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

NCT05332210 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

Myasthenia Gravis

Interventions

DRUG: HBM9161 Injection (680mg)

Sponsor

Harbour BioMed (Guangzhou) Co. Ltd.